Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis
- 6 September 2018
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 53 (3) , 276-284
Abstract
Objective: To review the efficacy, safety, and place in therapy of ixekizumab for the treatment of moderate to severe plaque psoriasis. Data Sources: PubMed (1966 to July 2018) and clinicaltrials.gov were searched using the terms ixekizumab, LY2439821, interleukin-17, and psoriasis. Study Selection and Data Extraction: Human studies published in peer-reviewed medical journals in English were used. Data Synthesis: The efficacy and safety of ixekizumab has been primarily reported by 4 phase III trials (UNCOVER-1, UNCOVER-2, UNCOVER-3, and UNCOVER-J) and multiple post hoc analyses. The average proportions of patients achieving a 75%, 90%, and 100% reduction in their Psoriasis Area and Severity Index (PASI) were 89%, 70%, and 38%, respectively, after 12 weeks of therapy. PASI75 was maintained for up to 3 years in 80.5% of participants. Ixekizumab was statistically significantly more effective than ustekinumab, with 76.5%, compared with 59%, of patients achieving PASI90 in 52 weeks. The most common adverse events include nasopharyngitis (14.1%), upper respiratory tract infections (7.9%), and injection-site reactions (6.8%), which are similar to that for other biological agents. The risk of inflammatory bowel disease may be increased with ixekizumab. Relevance to Patient Care and Clinical Practice: This review summarizes and evaluates clinical data regarding the efficacy and safety of ixekizumab and discusses relevant differences compared with other biological agents used for the management of chronic plaque psoriasis. Conclusions: Ixekizumab is a highly efficacious and well-tolerated treatment option for patients with moderate to severe plaque psoriasis.Keywords
This publication has 44 references indexed in Scilit:
- A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2014
- Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasisThe Journal of Clinical Pharmacology, 2014
- Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasisBritish Journal of Dermatology, 2013
- Living with Psoriasis: Prevalence of Shame, Anger, Worry, and Problems in Daily Activities and Social LifeActa Dermato-Venereologica, 2012
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque PsoriasisNew England Journal of Medicine, 2012
- Consensus Guidelines for the Management of Plaque PsoriasisArchives of Dermatology, 2012
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2011
- LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept studyArthritis & Rheumatism, 2010
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2009
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2008